未经证实:人类表皮生长因子受体2(HER2)阳性转移性乳腺癌患者尽管有多种抗HER2靶向治疗,但仍继续进展。许多研究发现,吡罗替尼,一种小分子泛ErbB受体酪氨酸激酶抑制剂(TKI),对HER2阳性转移性乳腺癌患者的治疗有效。本系统评价和荟萃分析旨在评估吡罗替尼治疗HER2阳性转移性乳腺癌的疗效和安全性。
未经授权:PubMed,Embase,WebofScience,和Cochrane图书馆数据库搜索到2022年2月。研究包括HER2阳性转移性乳腺癌在任何治疗线中接受吡罗替尼治疗,前瞻性和回顾性。对纳入研究的数据进行统计汇总和荟萃分析,以探讨吡罗替尼在HER2阳性转移性乳腺癌中的疗效和安全性。
未经评估:在此荟萃分析中,包括23项研究。在HER2阳性转移性乳腺癌患者中,Pyrotinib的总体客观缓解率为0.49(95%CI:0.40,0.58),在脑转移患者中为0.52(95%CI:0.32,0.71)。吡罗替尼的客观缓解率优于其他二线治疗(RR=1.38,95%CI:1.25,1.52),但相对不如曲妥珠单抗(T-DM1)(RR=0.82,95%CI:0.36,1.85).Pyrotinib在转移性乳腺癌和脑转移患者中的中位无进展生存期(PFSs)分别为8.2(95%CI:6.8,9.5)个月和8.9(95%CI:6.2,11.7)个月,分别。最常见的不良反应是腹泻,所有级别的发生率为0.84(95%CI:0.74,0.92),其次是恶心和呕吐0.52(95%CI:0.36,0.68)。
未经批准:在HER2阳性转移性乳腺癌的任何治疗方案中,含有吡罗替尼的方案显示出相当大的肿瘤反应,疾病控制,和生存与可控的不良反应。
UNASSIGNED: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients continue to progress despite multiple anti-HER2-targeted treatments. A number of studies have found that Pyrotinib, a small-molecule pan-ErbB receptor tyrosine kinase inhibitor (TKI), is effective in treating patients with HER2-positive metastatic breast cancer. This systematic
review and meta-analysis aimed to evaluate the efficacy and safety of Pyrotinib in the treatment of HER2-positive metastatic breast cancer.
UNASSIGNED: PubMed, Embase, Web of Science, and Cochrane Library databases were searched until February 2022. Research on HER2-positive metastatic breast cancer being treated with Pyrotinib in any line of therapy was included, both prospective and retrospective. Statistical pooling and meta-analysis of data from the included studies were performed to explore the efficacy and safety of Pyrotinib in HER2-positive metastatic breast cancer.
UNASSIGNED: In this meta-analysis, 23 studies were included. The overall objective response rate was 0.49 (95% CI: 0.40, 0.58) for Pyrotinib in HER2-positive metastatic breast cancer and 0.52 (95% CI: 0.32, 0.71) in those with brain metastases. The objective response rate of Pyrotinib was superior to that of other second-line therapeutics in comparison (RR =1.38, 95% CI: 1.25, 1.52), but was relatively inferior to trastuzumab emtansine (T-DM1) (RR =0.82, 95% CI: 0.36, 1.85). The combined median progression-free survivals (PFSs) for Pyrotinib in metastatic breast cancer and those with brain metastases were 8.2 (95% CI: 6.8, 9.5) months and 8.9 (95% CI: 6.2, 11.7) months, respectively. The most common adverse reaction was diarrhea with an all-grade incidence of 0.84 (95% CI: 0.74, 0.92), followed by nausea and vomiting of 0.52 (95% CI: 0.36, 0.68).
UNASSIGNED: In any line of treatment for HER2-positive metastatic breast cancer, the Pyrotinib-containing regimens demonstrated considerable tumor response, disease control, and survival with manageable adverse effects.